Skip to content

COPD and Cardiovascular Risk in the Population

COPD and Cardiovascular Risk in the Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00787748
Acronym
CORSAIB
Enrollment
623
Registered
2008-11-07
Start date
2006-10-31
Completion date
2008-06-30
Last updated
2012-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Chronic Obstructive Pulmonary Disease

Keywords

Cardiovascular, COPD, Population, Prevalence, Underdiagnosis

Brief summary

The prevalence of chronic obstructive pulmonary disease (COPD) in patients with cardiovascular disease (CVD) is unknown, and whether or not COPD is adequately diagnosed and treated in these patients has not been investigated before. We hypothesized that the prevalence of COPD would be significantly higher (30%) in patients with CVD than in the general population. Besides, we anticipated that COPD, a potentially treatable CV risk factor, would be undiagnosed in more than 80% of CVD patients.

Detailed description

We aim to compare clinical and spirometric data in three groups of individuals. Two of them are participants in an ongoing population-based study (CORSAIB) aimed at investigating the distribution of CVD risk factors in the general population of the Balearic Islands, Spain. The design and full methodological details of the CORSAIB study have been published elsewhere (Rigo F, et al. Rev Clin Espa 2005). A third group will include patients with stable CVD regularly visited at the referral hospital of our community. Inclusion criteria for the study are male and female individuals, aged 40 to 81 years, residents of the Balearic Islands, and who are willing to participate in this research.

Interventions

None listed

Sponsors

Fondo de Investigacion Sanitaria
CollaboratorOTHER
Cimera
Lead SponsorNETWORK

Study design

Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 81 Years
Healthy volunteers
Yes

Inclusion criteria

* residents of the Balearic Islands * willing to participate in this research * able to sign the written consent form

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
Prevalence of COPD defined according to the current GOLD guidelines as a post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <0.7.Current

Secondary

MeasureTime frame
Underdiagnosis of COPDCurrent
Undertreatment of COPDCurrent

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026